Immunotherapy is a cancer treatment modality that works by harnessing or modulating the immune response, and in this entry it is described as a therapy context used to evaluate outcomes, including a model that predicted deep hypergraph for nsclc-based immunotherapy outcomes in NSCLC. It is being applied across multiple malignancies, including oral precancer, prostate cancer, and breast cancer, with the latter discussed as an innovative treatment area where efficacy may be improved through interaction with ferroptosis. A phase I clinical trial of direct immunotherapy injection into oral precancer lesions reported tumor shrinkage with no dose-limiting toxicities, suggesting early safety and activity. In prostate cancer, immunotherapy combined with targeted therapy was assessed for both efficacy and safety, indicating a combination strategy rather than monotherapy. Recent literature also highlights a clinician-deployable deep hypergraph model integrating clinical and CT radiomics to predict immunotherapy outcomes in NSCLC, reflecting growing use of AI-guided treatment selection. Overall, the evidence spans predictive modeling, combination therapy, and local injection approaches, with mechanistic interest in ferroptosis as a potential enhancer of response.
NSCLC / Prediction
- A clinician-deployable deep hypergraph model integrating clinical and CT radiomics predicted immunotherapy outcomes in NSCLC, supporting outcome stratification in lung cancer care. (PMID:42008547)
- The model was described as integrating clinical and CT radiomics, highlighting a multimodal prediction framework for treatment response. (PMID:42008547)
Oral precancer
- Direct immunotherapy injection into oral precancer lesions produced tumor shrinkage in a phase I clinical trial. (PMID:42012894)
- The trial reported no dose-limiting toxicities, suggesting acceptable early safety for local administration. (PMID:42012894)
- The intervention was delivered directly into lesions, emphasizing a localized treatment strategy. (PMID:42012894)
Prostate cancer
- Combined immunotherapy and targeted therapy was evaluated for efficacy and safety in prostate cancer. (PMID:42017392)
- The study focused on a combination approach, indicating immunotherapy may be used alongside targeted agents rather than alone. (PMID:42017392)
Breast cancer / Ferroptosis
- Immunotherapy was discussed as a potential breast cancer treatment, with efficacy potentially improved by interaction with ferroptosis pathways. (PMID:42029800)
- The review specifically links modulation of ferroptosis mechanisms to enhanced immunotherapy efficacy. (PMID:42029800)
- This suggests a mechanistic avenue for improving response in breast cancer through cell-death pathway crosstalk. (PMID:42029800)